Engineering growth factors for regenerative medicine applications.

UNLABELLED Growth factors are important morphogenetic proteins that instruct cell behavior and guide tissue repair and renewal. Although their therapeutic potential holds great promise in regenerative medicine applications, translation of growth factors into clinical treatments has been hindered by limitations including poor protein stability, low recombinant expression yield, and suboptimal efficacy. This review highlights current tools, technologies, and approaches to design integrated and effective growth factor-based therapies for regenerative medicine applications. The first section describes rational and combinatorial protein engineering approaches that have been utilized to improve growth factor stability, expression yield, biodistribution, and serum half-life, or alter their cell trafficking behavior or receptor binding affinity. The second section highlights elegant biomaterial-based systems, inspired by the natural extracellular matrix milieu, that have been developed for effective spatial and temporal delivery of growth factors to cell surface receptors. Although appearing distinct, these two approaches are highly complementary and involve principles of molecular design and engineering to be considered in parallel when developing optimal materials for clinical applications. STATEMENT OF SIGNIFICANCE Growth factors are promising therapeutic proteins that have the ability to modulate morphogenetic behaviors, including cell survival, proliferation, migration and differentiation. However, the translation of growth factors into clinical therapies has been hindered by properties such as poor protein stability, low recombinant expression yield, and non-physiological delivery, which lead to suboptimal efficacy and adverse side effects. To address these needs, researchers are employing clever molecular and material engineering and design strategies to both improve the intrinsic properties of growth factors and effectively control their delivery into tissue. This review highlights examples of interdisciplinary tools and technologies used to augment the therapeutic potential of growth factors for clinical applications in regenerative medicine.

[1]  L. Pannell,et al.  Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. , 1997, The Biochemical journal.

[2]  J. Cochran,et al.  An engineered dimeric fragment of hepatocyte growth factor is a potent c‐MET agonist , 2014, FEBS letters.

[3]  L. E. Umoru,et al.  Natural Products: A Minefield of Biomaterials , 2012 .

[4]  Antonios G Mikos,et al.  Gelatin as a delivery vehicle for the controlled release of bioactive molecules. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Zhifeng Xiao,et al.  Collagen scaffolds loaded with collagen-binding NGF-beta accelerate ulcer healing. , 2009, Journal of biomedical materials research. Part A.

[6]  Zhifeng Xiao,et al.  Linear ordered collagen scaffolds loaded with collagen-binding brain-derived neurotrophic factor improve the recovery of spinal cord injury in rats. , 2009, Tissue engineering. Part A.

[7]  Robert Goldman,et al.  Growth Factors and Chronic Wound Healing: Past, Present, and Future , 2004, Advances in skin & wound care.

[8]  Raymond M. Wang,et al.  Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction. , 2015, Biomaterials.

[9]  V. Sasisekharan,et al.  Structural specificity of heparin binding in the fibroblast growth factor family of proteins , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  F. Veronese PEGylated protein drugs , 2015 .

[11]  Jennie B. Leach,et al.  Extracellular Matrix , 2015, Neuromethods.

[12]  Stephen F Badylak,et al.  Biomaterials for tissue engineering applications. , 2014, Seminars in pediatric surgery.

[13]  G. Neufeld,et al.  VEGF145, a Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular Matrix* , 1997, The Journal of Biological Chemistry.

[14]  M. Jewett,et al.  Mimicking the Escherichia coli cytoplasmic environment activates long‐lived and efficient cell‐free protein synthesis , 2004, Biotechnology and bioengineering.

[15]  S. Bass,et al.  Selecting high-affinity binding proteins by monovalent phage display. , 1991, Biochemistry.

[16]  D. Lauffenburger,et al.  Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.

[17]  J. Haugh Mathematical Model of Human Growth Hormone (hGH)‐Stimulated Cell Proliferation Explains the Efficacy of hGH Variants as Receptor Agonists or Antagonists , 2004, Biotechnology progress.

[18]  E. Gherardi,et al.  Protein engineered variants of hepatocyte growth factor/scatter factor promote proliferation of primary human hepatocytes and in rodent liver. , 2012, Gastroenterology.

[19]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[20]  C. Cho,et al.  Construction of a Novel Extracellular Matrix using a New Genetically Engineered Epidermal Growth Factor Fused to IgG-Fc , 2005, Biotechnology Letters.

[21]  Yasuhiko Tabata,et al.  Enhanced bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. , 2006, Tissue engineering.

[22]  J. Wells,et al.  Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity. , 1999, Biochemistry.

[23]  S. Rizzi,et al.  Hyaluronic acid: evaluation as a potential delivery vehicle for vitronectin:growth factor complexes in wound healing applications. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Mikaël M. Martino,et al.  Extracellular Matrix-Inspired Growth Factor Delivery Systems for Skin Wound Healing. , 2015, Advances in wound care.

[25]  J. Cochran,et al.  Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists , 2011, Proceedings of the National Academy of Sciences.

[26]  M. O’Connor-McCourt,et al.  Superagonistic activation of ErbB-1 by EGF-related growth factors with enhanced association and dissociation rate constants. , 2000, The Journal of biological chemistry.

[27]  A. Sahni,et al.  Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. , 2000, Blood.

[28]  Jens-Peter Volkmer,et al.  Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.

[29]  Jennifer L. Lahti,et al.  Engineered epidermal growth factor mutants with faster binding on‐rates correlate with enhanced receptor activation , 2011, FEBS letters.

[30]  D. Mooney,et al.  Growth factor delivery-based tissue engineering: general approaches and a review of recent developments , 2011, Journal of The Royal Society Interface.

[31]  Daniel Broszczak,et al.  Human pilot studies reveal the potential of a vitronectin: growth factor complex as a treatment for chronic wounds , 2011, International wound journal.

[32]  Harald C Ott,et al.  Organ engineering based on decellularized matrix scaffolds. , 2011, Trends in molecular medicine.

[33]  H. Ploegh,et al.  Sortase-catalyzed transformations that improve the properties of cytokines , 2011, Proceedings of the National Academy of Sciences.

[34]  C. Powers,et al.  Fibroblast growth factors, their receptors and signaling. , 2000, Endocrine-related cancer.

[35]  W. Murphy,et al.  Design of growth factor sequestering biomaterials. , 2014, Chemical communications.

[36]  Matthias P Lutolf,et al.  Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. , 2007, Biomaterials.

[37]  Adrian Whitty,et al.  Understanding cytokine and growth factor receptor activation mechanisms , 2012, Critical reviews in biochemistry and molecular biology.

[38]  M. Lefranc,et al.  A simple luciferase assay for signal transduction activity detection of epidermal growth factor displayed on phage. , 1997, Nucleic acids research.

[39]  Adrian Ranga,et al.  Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix , 2013, Proceedings of the National Academy of Sciences.

[40]  J. Hubbell,et al.  Engineered insulin-like growth factor-1 for improved smooth muscle regeneration. , 2012, Biomaterials.

[41]  E. J. V. van Zoelen,et al.  Ligand-induced Lysosomal Epidermal Growth Factor Receptor (EGFR) Degradation Is Preceded by Proteasome-dependent EGFR De-ubiquitination* , 2003, Journal of Biological Chemistry.

[42]  C. Mason,et al.  A brief definition of regenerative medicine. , 2008, Regenerative medicine.

[43]  Philip T. Pienkos,et al.  Growth factor engineering by degenerate homoduplex gene family recombination , 2002, Nature Biotechnology.

[44]  S. Seif-Naraghi,et al.  Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor. , 2012, Acta Biomaterialia.

[45]  Mikaël M. Martino,et al.  The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  Milica Radisic,et al.  Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. , 2010, Biomaterials.

[47]  Ja Hubbell,et al.  Matrix-bound growth factors in tissue repair. , 2006, Swiss medical weekly.

[48]  N. Ferrara Binding to the Extracellular Matrix and Proteolytic Processing: Two Key Mechanisms Regulating Vascular Endothelial Growth Factor Action , 2010, Molecular biology of the cell.

[49]  Jeffrey J. Rice,et al.  Tenascin C Promiscuously Binds Growth Factors via Its Fifth Fibronectin Type III-Like Domain , 2013, PloS one.

[50]  Olena Kravchuk,et al.  Vitronectin: growth factor complexes hold potential as a wound therapy approach. , 2008, The Journal of investigative dermatology.

[51]  N. Epstein,et al.  Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount , 2013, Surgical neurology international.

[52]  M. Iruela-Arispe,et al.  Extracellular matrix, inflammation, and the angiogenic response. , 2010, Cardiovascular research.

[53]  Jihun Lee,et al.  Increased Functional Half-life of Fibroblast Growth Factor-1 by Recovering a Vestigial Disulfide Bond , 2013 .

[54]  David Silverstein,et al.  Growth factor binding to the pericellular matrix and its importance in tissue engineering. , 2007, Advanced drug delivery reviews.

[55]  M. Shoichet,et al.  Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy , 2010, Breast Cancer Research.

[56]  D A Lauffenburger,et al.  Intracellular Trafficking of Epidermal Growth Factor Family Ligands Is Directly Influenced by the pH Sensitivity of the Receptor/Ligand Interaction (*) , 1995, The Journal of Biological Chemistry.

[57]  Jacqueline Murray,et al.  Heparin-II Domain of Fibronectin Is a Vascular Endothelial Growth Factor-Binding Domain: Enhancement of VEGF Biological Activity by a Singular Growth Factor/Matrix Protein Synergism , 2006, Circulation research.

[58]  S. Werner,et al.  Regulation of wound healing by growth factors and cytokines. , 2003, Physiological reviews.

[59]  T. Nakamura,et al.  Collagens in the liver extracellular matrix bind hepatocyte growth factor. , 1998, Gastroenterology.

[60]  Daa Lipovek,et al.  Library Construction For Protein Engineering , 2009 .

[61]  Alan Wells,et al.  Engineering epidermal growth factor for enhanced mitogenic potency , 1996, Nature Biotechnology.

[62]  Shaun M Lippow,et al.  Improved mutants from directed evolution are biased to orthologous substitutions. , 2006, Protein engineering, design & selection : PEDS.

[63]  Mikaël M. Martino,et al.  Biomimetic materials in tissue engineering , 2010 .

[64]  Nobuyuki Itoh,et al.  Fibroblast growth factors , 2001, Genome Biology.

[65]  A. Sahni,et al.  FGF‐2 but not FGF‐1 binds fibrin and supports prolonged endothelial cell growth , 2003, Journal of thrombosis and haemostasis : JTH.

[66]  Anna T Grazul-Bilska,et al.  Wound healing: the role of growth factors. , 2003, Drugs of today.

[67]  K D Wittrup,et al.  Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. , 1999, Journal of molecular biology.

[68]  Jeffrey A. Hubbell,et al.  Cell-Demanded Liberation of VEGF121 From Fibrin Implants Induces Local and Controlled Blood Vessel Growth , 2004, Circulation research.

[69]  D. M. Brown,et al.  An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. , 1996, Journal of molecular biology.

[70]  Junho Park,et al.  Overproduction of recombinant human hepatocyte growth factor in Chinese hamster ovary cells. , 2010, Protein expression and purification.

[71]  Ralph Müller,et al.  Engineering the Growth Factor Microenvironment with Fibronectin Domains to Promote Wound and Bone Tissue Healing , 2011, Science Translational Medicine.

[72]  D. Craik Joseph Rudinger memorial lecture: Discovery and applications of cyclotides , 2013, Journal of peptide science : an official publication of the European Peptide Society.

[73]  R. Derynck,et al.  Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. , 1991, Cell regulation.

[74]  Nobuyuki Itoh,et al.  Characterization of Growth Factor-binding Structures in Heparin/Heparan Sulfate Using an Octasaccharide Library* , 2004, Journal of Biological Chemistry.

[75]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[76]  Martin Ehrbar,et al.  Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[77]  J. Hubbell,et al.  Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[78]  S J Prestrelski,et al.  Factors affecting short-term and long-term stabilities of proteins. , 2001, Advanced drug delivery reviews.

[79]  Alexander Huber,et al.  The effects of processing methods upon mechanical and biologic properties of porcine dermal extracellular matrix scaffolds. , 2010, Biomaterials.

[80]  G. Schultz,et al.  Interactions between extracellular matrix and growth factors in wound healing , 2009, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[81]  Mikaël M. Martino,et al.  Extracellular matrix-inspired growth factor delivery systems for bone regeneration. , 2015, Advanced drug delivery reviews.

[82]  J. Turnbull,et al.  Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. , 2011, The Journal of endocrinology.

[83]  C. Sarkar,et al.  Cell-free Display Systems For Protein Engineering , 2009 .

[84]  Stephen F Badylak,et al.  Decellularization of tissues and organs. , 2006, Biomaterials.

[85]  H. Polk,et al.  Enhancement of epidermal regeneration by biosynthetic epidermal growth factor , 1986, The Journal of experimental medicine.

[86]  F. V. Cochran,et al.  Cell Surface Display Systems For Protein Engineering , 2009 .

[87]  M. Götte,et al.  Functions of cell surface heparan sulfate proteoglycans. , 1999, Annual review of biochemistry.

[88]  Jennifer R Cochran,et al.  Discovery of improved EGF agonists using a novel in vitro screening platform. , 2011, Journal of molecular biology.

[89]  Hui Zhao,et al.  The effect of collagen-binding NGF-beta on the promotion of sciatic nerve regeneration in a rat sciatic nerve crush injury model. , 2009, Biomaterials.

[90]  Byung-Soo Kim,et al.  Comparison between heparin-conjugated fibrin and collagen sponge as bone morphogenetic protein-2 carriers for bone regeneration , 2012, Experimental & Molecular Medicine.

[91]  A. Giaccia,et al.  An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. , 2014, Nature chemical biology.

[92]  Mikaël M. Martino,et al.  Growth Factors Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing , 2014, Science.

[93]  Y. Tabata,et al.  Regeneration of Canine Tracheal Cartilage by Slow Release of Basic Fibroblast Growth Factor from Gelatin Sponge , 2006, ASAIO journal.

[94]  Richard T. Lee,et al.  Intraarticular injection of heparin-binding insulin-like growth factor 1 sustains delivery of insulin-like growth factor 1 to cartilage through binding to chondroitin sulfate. , 2010, Arthritis and rheumatism.

[95]  G. Weiss,et al.  Optimizing the affinity and specificity of proteins with molecular display. , 2006, Molecular bioSystems.

[96]  R. Dinarvand,et al.  Growth factor conjugation: strategies and applications. , 2015, Journal of biomedical materials research. Part A.

[97]  Matthias P Lutolf,et al.  Biopolymeric delivery matrices for angiogenic growth factors. , 2003, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[98]  J G Flanagan,et al.  Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells , 1992, Molecular and cellular biology.

[99]  J M Davidson,et al.  Sustained release of epidermal growth factor accelerates wound repair. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[100]  Yoshihiro Ito,et al.  Covalently immobilized biosignal molecule materials for tissue engineering. , 2007, Soft matter.

[101]  E. Schönherr,et al.  Extracellular Matrix and Cytokines: A Functional Unit , 2000, Developmental immunology.

[102]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[103]  W. Stemmer DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. , 1994, Proceedings of the National Academy of Sciences of the United States of America.